Online citations, reference lists, and bibliographies.
← Back to Search

Assessing The Completeness And Correctness Of The Registration Of Malignant Mesothelioma In Belgium.

M. Rosskamp, H. De Schutter, K. Henau, K. Nackaerts, J. Van Meerbeeck, M. Praet, L. van Eycken
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVES Malignant mesothelioma (MM) is a rare and aggressive cancer mostly caused by asbestos exposure, and for which the diagnosis is difficult. This study aimed to assess the completeness and correctness of MM registration using 3 independent national databases: the Belgian Cancer Registry (BCR), the population-based mortality statistics (certificates of death, COD), and the Belgian Mesothelioma Registry (BMR). METHODS The study cohort included all MM reported to the BCR and diagnosed between 2004 and 2012 (n = 2292), all patients reviewed by the pathology commission of the BMR (2004-2012; n = 2019), and COD data for all Belgian citizens (2004-2013). Available data were compared in terms of registered cases, histological diagnosis, performed immunohistochemical (IHC) tests, and IHC test results. RESULTS Comparison of BCR with BMR registrations showed 94.8% concordant cases. The proportion of MM diagnoses originally reported to BCR with unspecified MM morphology was reduced from 25.8% to less than 1%. RESULTS from IHC tests were available for 95.3% of concordant MM cases. Different IHC patterns could be distinguished by MM histology. MM cases registered at BCR for which COD mentioned an MM as underlying cause of death represented 76.4% of deceased cases. MM long-term survivors (survival >3 years; 10.9%) were characterised by distinct clinical and biological characteristics. CONCLUSIONS A comparison of independent Belgian MM registration databases elucidated under-registration and misclassification and revealed possible reasons for observed discordances. Combining all the available information resulted in enhanced completeness and correctness of MM registration in Belgium and allowed for the identification and characterisation of MM long-term survivors.
This paper references
Novel insights into mesothelioma biology and implications for therapy
T. Yap (2017)
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
The epithelioid BAP1‐negative and p16‐positive phenotype predicts prolonged survival in pleural mesothelioma
A. Chou (2018)
Certified causes of death in patients with mesothelioma in South East England
C. Okello (2008)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
Malignant Mesothelioma and Its Non-Asbestos Causes.
R. Attanoos (2018)
Asbestos in Belgium: an underestimated health risk. The evolution of mesothelioma mortality rates (1969–2009)
Laura Van den Borre (2014)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Distinctive clinical characteristics of malignant mesothelioma in young patients
A. Thomas (2015)
Surveillance of mesothelioma and workers' compensation in British Columbia, Canada
Tracy L Kirkham (2010)
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
D. Camidge (2006)
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
T. Hida (2017)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
Chimed-Ochir Odgerel (2017)
Mesothelioma mortality in Great Britain from 1968 to 2001.
D. McElvenny (2005)
Malignant Mesothelioma Surveillance: A Comparison of ICD 10 Mortality Data with SEER Incidence Data in Nine Areas of the United States
G. Pinheiro (2004)
International statistical classification of diseases and related health problems. Tenth revision.
Brämer Gr (1988)
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.
D. Marciniuk (2012)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Y. Kinoshita (2018)
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
The completeness of the Swedish Cancer Register – a sample survey for year 1998
L. Barlow (2009)
Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study
A. Trama (2017)
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
Cause-specific mortality: understanding uncertain tips of the disease iceberg.
M. Goldacre (1993)
Endometriosis diagnosis and staging by operating surgeon and expert review using multiple diagnostic tools: an inter‐rater agreement study
K. Schliep (2017)
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
The Scottish Record Linkage System.
S. Kendrick (1993)
Interrater reliability: the kappa statistic
M. McHugh (2012)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar